Standard BioTools (LAB) news
Recent news
Standard Biotools: Financial terms were not disclosed
Standard BioTools Inc. (NASDAQ: LAB) has announced that it will release its second quarter 2026 financial results on Wednesday, August 5, 2026, following the close of U.S. markets. The company has not disclosed specific financial terms related to its recent activities or transactions. Standard…
AInvest Wire · Oct 5, 2026Standard Biotools reports pact to sell microfluidics business
Standard BioTools Inc. (NASDAQ: LAB) has announced the termination of its prior agreement to sell its Mass Cytometry business to Multiplex Bio and the execution of a new purchase agreement with Element Biosystems, a subsidiary of GMT Venture Partners, for $5.5 million in cash . This transaction…
AInvest Wire · Oct 5, 2026Standard Biotools - Deal expected to close in about 30 days
AInvest Wire · Oct 5, 2026Standard Biotools announces agreement to sell microfluidics business to Archimed
AInvest Wire · Oct 5, 2026Standard Biotools provides update on sale of mass cytometry business
Standard BioTools Inc. (NASDAQ: LAB) has completed the sale of its SomaLogic business to Illumina, Inc. (NASDAQ: ILMN) for $350 million in upfront cash, with potential additional payments of up to $75 million based on performance targets for 2025 and 2026. The transaction also includes a 2% royalty…
AInvest Wire · Sep 30, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.